A NEW CORNERSTONE IN IMMUNOMODULATION

May 2026

BioInvent

Disclaimer

This presentation is not a prospectus or other offer document and has not been approved by any regulatory authority in any jurisdiction. The information contained in this presentation has been prepared solely for information purposes. It is not intended for potential investors and does not constitute or form part of, and should not be construed as, an offer or solicitation of an offer to subscribe for or purchase any shares or any other securities in BioInvent International AB ("BioInvent"). This presentation does not purport to contain comprehensive or complete information about the company. Neither shall the presentation or any part of it, nor the fact of its distribution or communication, form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation thereto. Any decision to invest in any securities of the company should only be made on the basis of a thorough and independent investigation of the company itself and not on the basis of this presentation.

This presentation contains forward-looking statements, which are subject to risks and uncertainties because they relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking statements give BioInvent's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of BioInvent or the industry in which it operates, to be materially different than any future results, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. BioInvent will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority. The information included in this presentation may be subject to updating, completion, revision and amendment and such information may change materially.

BioInvent is under no obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. BioInvent make no guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. BioInvent does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.

BioInvent
bringing antibodies to life

BioInvent is Developing the New Standard of Care for Recurring Ovarian Cancer

- $1.5 billion in estimated peak sales

We are Developing Next-generation IO Therapies Designed to Address One of the Biggest Remaining Unmet Needs in Cancer Treatment

What the opportunity is

Checkpoint inhibitors created a major oncology market

Many patients still fail to respond due to resistance

Large pharma seeks differentiated next-generation IO combinations ahead of the PD-1 patent cliff

Why BioInvent

BI-1808 and BI-1206 target immune resistance beyond current therapies

Strong anti-tumor activity with favorable safety profile

Potential to enhance efficacy and durability of existing immunotherapies



Why we are well-positioned

Proprietary human-first platform with in-house manufacturing

Multiple Phase 2 studies with upcoming readouts

Proven strategic partnerships backed by leading global healthcare investors

Human biology first. Platform-driven discovery. Breakthrough therapeutics.

The Immuno-Oncology (IO) Market Continues to Grow as Licensing Activity Accelerates

The immuno-oncology market is a $168bn opportunity...



...but there is a few bottlenecks[2]

1. **Immunosuppressive tumor microenvironment**
2. Tumor heterogeneity
3. Low immunogenicity of tumor
4. Lack of suitable target antigens
5. Clinically relevant biomarkers

BioInvent targets the #1 challenge in IO therapy

Notes: 1) Other include cancer vaccines, oncolytic viruses and cytokines, 2) High-Prescriber Survey (March 2025)
Source: GlobalData.

Key insights

$64bn

Checkpoint Modulators market in 2025. BioInvent's core target market.

$150bn

US & EU IO licensing deal value reached peak levels in 2023, highlighting strong partnering demand

The Coming IO Patent Cliff Creates a Strategic Opening

Key IO therapies facing loss of exclusivity

Drug (brand)	Company	Target	2025 sales	Earliest expected LOE / biosimilar entry		Notes
				US	EU	
KEYTRUDA (pembrolizumab)	MERCK	PD-1	$31.6bn	**2028** (earliest)	**~2031** (earliest)	Numerous patents expire 2028-2031 across key markets
OPDIVO (nivolumab)	Bristol Myers Squibb	PD-1	$10.0bn	**2028** (earliest)	**~2030** (earliest)	Broad patent estate with key expiry 2028-2030
TECENTRIQ atezolizumab	Roche	PD-L1	$4.6bn[1)]	**~2029-2031**	**~2029-2032**	PD-L1 class patents expire across 2028-2035
IMFINZI durvalumab	AstraZeneca	PD-L1	$6.0bn	**~2029-2031**	**~2029-2032**	PD-L1 class patents expire across 2028-2035
LIBTAYO (Cemiplimab)	SANOFI REGENERON	PD-1	$1.4bn	**~2032**	**~2033**	Later LOE relative to other PD-1 franchises

Source: FactSet as of 2026-05-07. Note(s): 1) CHF/USD exchange rate of 1.29 used for conversion

What this means

- **~$56bn in annual sales** exposed to biosimilar competition
- Large pharma will need **new mechanisms to defend, extend or replace revenue streams**
- **Strong strategic incentive to partner** on **differentiated assets** that enhance **PD-1 / PD-L1 therapies**
- **Combination innovation** will be **critical** to drive **differentiation and sustain growth**

BioInvent Could Help Unlock the Full Potential of Immuno-Oncology (IO)

Checkpoint inhibitors: transformative, but response rates remain inadequate

The Challenge

- **Too few patients respond**
  No response or less than 25% in many solid tumors
- **Responses often don't last**
  Relapses and progression common
- **Tumors develop resistance**
  Tumor microenvironment (TME)
- **IO still has untapped potential**
  Current therapies not optimized

Impact on patients today

- **Many patients still do not respond**
- **Responses are often not durable**
- **Resistance limits long-term benefit**
- **Outcomes remain suboptimal**

How BioInvent is different

- **Increase response rates**
- **Favorable safety enables broader use**
- **Deliver deeper and longer-lasting responses**
- **Target resistance in the TME**
- **Unlock the full potential of IO**



BioInvent has First-in-class Clinical Assets Advancing Across Multiple Indications



1L: First line treatment
CTCL: Cutaneous T-cell Lymphoma, NHL: Non-Hodgkin's Lymphoma, FL: Follicular Lymphoma, MCL: Mantle Cell Lymphoma, MZL: Marginal Zone Lymphoma, NSCLC: Non-small cell lung cancer
Notes: 1) Supply agreement with Merck, 2) Supply agreement with AstraZeneca

BioInvent Phase 1/2 Responses Demonstrate Strong Anti-tumor Activity

200+ patients have so far been included in BI-1808 and BI-1206 clinical trials • ~ 50 patients with CRs and PRs combined

Complete Response (CR)

Tumor disappears



Partial Response (PR)

Tumor shrinks



Why this matters

- *Strong signal of drug efficacy*
- *Large unmet medical need for new, safer treatments with longer duration of response*
- *Supports progression to later-stage and registrational trials*

Despite Global Dominance in Oncology, Pembrolizumab has Demonstrated Underwhelming Response Rates in Ovarian Cancer

BioInvent's BI-1808 + pembrolizumab are outperforming pembro alone (Phase 2a data)

PROC response rates



Platinum resistant ovarian cancer (PROC), Objective Response Rate (ORR), Disease Control Rate (DCR)



BI-1808 in Ovarian Cancer – Reactivates Immune System by Targeting Tregs

Transitioning the microenvironment from tumor friendly to tumor hostile

Targets TNFR2 on Tregs, reducing tumor-driven immune suppression



BI-1808

BI-1808 induces Treg depletion and myeloid reprogramming to unleash CD8+ T cells



Best-in-class potential

First-in-class TNFR2 antibody with strong efficacy/safety profile

TNFR2 = Immune receptor regulating suppressive Tregs

Enhances the effect of standard therapies

Response in combination[1]



Combination potential

Designed for combination with existing therapies like Keytruda® and other standard-of-care treatments

Strong safety profile

Well-tolerated in early clinical studies

Durable responses

Durable responses observed (up to ~3 years)

Opportunity

Large and expanding combination market

Notes: 1) ORR In combination with Keytruda Pembrolizumab in MSS CRC (NCT05493767), 2) Durability data from ongoing clinical programs across indications; complete responses up to ~3 years observed in some patients.

BI-1808 and BI-1206 Have the Potential for Significant Revenue Growth Through Label Expansions

Label expansion…

Most cancer treatments target tumor-expressed antigens and are restricted to a **limited set of tumor types**

Immunomodulatory agents have much broader potential to target multiple **tumor types,** building substantial revenue over time

BioInvent's "fast-to-market" strategy aims to select a first indication as a springboard to achieve **high revenue growth through label expansions**

BI-1808 and BI-1206 should provide **superior efficacy** in combination with pembrolizumab, in all indications for which pembro is approved

KEYTRUDA (pembrolizumab) sales from 2014-2027E ($bn)

Demonstrated that label expansion can drive substantial revenue growth over time



Sources: Statista (2014-2025), FactSet 2026E-2027E estimates

A Pragmatic Development Strategy With Billion-Dollar Potential

BI-1808 market potential in multiple cancer types

- Pursue **Fast to market** indication in CTCL (plan for BTD and accelerated approval)
- **Develop triplet regimen** with BI-1808+pembrolizumab+paclitaxel in PROC
- Future development options include:
  - Earlier lines of ovarian cancer in combination with pembro+paclitaxel
  - Other myeloid-driven tumors (eg, MSS Colorectal cancer or pancreatic cancer)
  - Other "cold" tumors



CTCL: Cutaneous T-Cell Lymphoma; PROC: Platinum Resistant Ovarian Cancer BTD: Breakthrough Designation

BioInvent's BI-1808 as the Next Standard of Care in Ovarian Cancer

If BI-1808 Target Product Profile in PROC is met, the peak sales is estimated at ~$1.5 billion (base-case)

CURRENT

- Standard of care (**SoC**) in ovarian cancer the chemotherapy drug paclitaxel added to Keytruda, but **survival still poor**

NEXT

- BI-1808 on top of current SoC: preclinical results show **effect beyond current therapies**
- **In upside**, all-comer case: % increase in potential patients will yield similar % increase in peak sales

FORECAST

Region	Peak Sales	Peak Year
US Sales ($K)	$988,608	2037
EU5 Sales ($K)	$396,504	2042
Japan Sales ($K)	$82,250	2042
7MM Total Sales ($K)	**$1,719,786**	**2043**



SoC: a recognized benchmark of competence, quality, and broadly accepted practice. This is a very preliminary 7MM forecast, given the early stage of the program. Many assumptions are placeholders until more is known about the program, its' data and the market. Current assumptions have not been tested in market research.

What Successful Oncology Assets are Worth and Why it Maps

Comparable IO assets command multi billion-dollar deal values



MorphoSys / Incyte	Merck / LaNova	Genmab / AbbVie	AbbVie / RemeGen	Pfizer / 3SBio	Gilead / MacroGenics	Genmab / AbbVie (platform)	Merck / Daiichi Sankyo
Late-stage B-cell lymphoma antibody partnership; strong commercial and ex-US licensing competitor	Phase 1 PD-1/VEGF bispecific; proves >$500m upfront even pre-Phase 2; floor valuation reference	CD20 bispecific benchmark with best-in-class economics; high-end valuation reference	PD-1/VEGF bispecific; closest mechanism match to BI-1206; validates ADC combination strategy	Largest upfront in PD-1/VEGF class; sustained big pharma appetite; high-end valuation reference	Early-stage bispecific collaboration; demonstrates strategic value of differentiated immune-modulating antibody platforms	Early-stage TNFR2 licensing deal; closest direct target comp for mechanism	Broad oncology collaboration; highlights strong big pharma appetite for differentiated antibody assets with multi-indication potential

Source: Company press releases

Backed by Leading Global Biotech Investors for the Next Phase of Growth

Why this matters

Deep due diligence
Top-class biotech investors with proven expertise

Long-term capital
Institutional investors with a long-term investment horizon

Ability to fund development
Strong financial backing to accelerate clinical programs

Investor takeaway

Validated by specialist investors

Top investors	About the investor	Selected successful investments			Ownership
Redmile Group	Leading US biotech investor with deep domain expertise and active ownership	BIONTECH — *COVID-19 vaccine leader*	immunogen — *acquired by AbbVie for $10B*	ARRAY BIOPHARMA — *Acquired by Pfizer for $11B*	15.2%
Van Herk Groep	Global biotech investor with a strong track record of building leading biopharma companies	ZEALAND PHARMA — *Rare disease leader*	argenx — *Vyvgart® (efgartigimod)*	Ablynx — *Acquired by Sanofi for $3.9B*	13.8%
Forbion.	Forbion is a leading venture capital firm working with Scientists/entrepreneurs to build companies	argenx — *Vyvgart® (efgartigimod)*	Versanis — *Acquired by Eli Lilly for 2b*	uniQure — *AMT-061 (hemophilia B) approved (US, EU)*	9.8%
HBM Healthcare Investments	Global healthcare investor backing high-growth and transformative companies.	ABIVAX — *RNA immune-modulation*	argenx — *Vyvgart® (efgartigimod)*	CATHAY INDUSTRIAL BIOTECH — *Industrial synthetic-biology leader*	7.7%
OMEGA FUNDS	Global life sciences investor focused on the world's most urgent medical needs	IMMUNOCORE — *First TCR therapy approved*	bridgebio — *Rare disease Nasdaq IPO*	Prevail THERAPEUTICS — *Acquired by Lilly for $1B*	3.8%
AP FJÄRDE AP-FONDEN	Swedish national pension fund deploying long-term capital into high-conviction listed and private biotech	BIOARCTIC — *Lecanemab® approved (US, EU)*	camurus. — *Buvidal® approved*	calliditas THERAPEUTICS — *Acquired by Asahi Kasei for $1.2B*	6.1%
Total ownership by top investors: 56.4%					

Note: Ownership percentage are approximate and collected Dec 31, 2025.

Key Expected Milestones 2026-2027



Upcoming KOL event: June 11 (BI-1206 in NHL and BI-1808 in CTCL)

1L/2L: First/second line treatment
CTCL: Cutaneous T-cell Lymphoma, NHL: Non-Hodgkin's Lymphoma, FL: Follicular Lymphoma, MCL: Mantle Cell Lymphoma, MZL: Marginal Zone Lymphoma, NSCLC: Non-small cell lung cancer

Why invest in BioInvent now?

1. **Improving the Effectiveness of the World's Leading Cancer Therapies**
2. **Two Clinical Assets Developed from Proprietary Human-First Platforms**
3. **Strong Anti-Tumor Activity Combined with Favorable Safety**
4. **Multiple Strategic Licensing and Partnering Opportunities**
5. **Backed by Leading Global Biotech Investors**

Improving the effectiveness and safety of the world's leading cancer therapies

BioInvent Phase 2 programs BI-1808 and BI-1206

ANTI-TNFR2

BI-1808 in Ovarian Cancer

BI-1808 in T-cell Lymphoma

BioInvent

BI-1808 in Ovarian Cancer

The Treatment Paradigm is Shaped by Platinum Sensitivity and Biomarker Status; With Few Recent Approvals in PROC



PROC : Platinum-Resistant Ovarian Cancer

1. Poveda A et al Lancet Oncol. 2021 May;22(5):620-631
2. Mirza MR et al N Engl J Med. 2016 Dec 1;375(22):2154-2164.
3. Aghajanian C J et al. Clin Oncol. 2012 Jun 10;30(17):2039-45.
4. Coleman RL et al. Lancet. 2017 Oct 28;390(10106):1949-1961
5. Hanker LC, et al. Ann Oncol. 2012;23(10):2605-12
6. González-Martín et al. Ann Oncol. 2023 Oct;34(10):833-848

BI-1808: Promising Efficacy in Ovarian Cancer (OC)

Phase 2a Design

Phase / Design	Population	N	Dosing	Sites	Key Endpoints	Data Cut-off
Ph2a single arm (doublet)	OC (all subtypes)	25 of 40	BI-1808 1000 mg Q3W Pembro 200 mg Q3W	8 (OC) in EU & UK	Safety ORR exploratory	2026-04-20

BI-1808 in combination with pembrolizumab

24% ORR, 56% DCR in 25 evaluable OC patients
Early mPFS 10.3 months

- 1 long lasting Complete Response (CR)
- 5 patients with Partial Response (PR)
- 8 patients with Stable Disease (SD), several durable SD beyond ten months and ongoing

- Safe and well-tolerated; all adverse events manageable with standard medical treatments
- Strong activity in both high-grade serous and clear cell ovarian cancer subtypes
- Expected final readout in H2 2026



ORR: Overall Response Rate
DCR: Disease Control Rate

BI-1808 Phase 2a Combo Data Shows Promising Efficacy in Ovarian Cancer (cont'd)



Data cut-off 2026-02-18

WHAT'S NEXT? Poster at ASCO 2026, May 30

OC: Ovarian Cancer

BI-1808 Clinical Trial Design Phase 1/2A (KEYNOTE-D20)



Positioning BI-1808 in Recurring Ovarian Cancer

- **First-in-class BI-1808** depletes immunosuppressive Tregs and reprograms macrophages to expand and activate CD8+ effector T cells, converting the tumor microenvironment from “cold" to “hot."
- Pembrolizumab + paclitaxel achieved 53% ORR, and **18.2 months of OS**,[1] establishing a **new standard of care** in recurring ovarian cancer. It was approved by the FDA in February 2026.
- **BI-1808 + pembrolizumab** current on a **24% ORR and 57% DCR** in recurring OC patients, representing a **meaningful improvement** over the **8% ORR of pembrolizumab** monotherapy, in addition to a target-validating CR in an OC patient treated with BI-1808 monotherapy.
- While **ADCs** show relatively high ORR (44-57% ORR), PFS (and eventually OS) is **not better** than the lasting responses that can be achieved with immunotherapy, based on available data and experience with chemotherapeutic agents
- **Adding BI-1808 to pembrolizumab + paclitaxel** is a biomarker-agnostic treatment expected to **enhance efficacy** higher than the 53% KEYNOTE-B96 benchmark with a more **durable** activation of the immune response, establishing a new SOC in recurring Ovarian Cancer.
- This regimen will **not compete with ADCs** in development which can be administered prior or after treatment with this regimen

[1]KEYNOTE-B96, ESMO 2025
PFS: Progression-Free Survival, OS: Overall Survival

BI-1808 in CTCL

Impressive Responses Were Observed in Heavily Pre-treated Patients with PTCL or CTCL Treated with BI-1808 Monotherapy

Case Studies

PTCL Patient (stage IV, 6 prior lines of treatment)	**CTCL Patient** (stage IIb MF, 5 prior lines of treatment)



Baseline Week 9



Baseline Week 21

BI-1808 Shows Promising Efficacy in **CTCL and PTCL**

EHA 2026 abstract Phase 2a monotherapy and combination data (cut-off Feb 2026)

- **40% objective response rate (ORR) as single agent in heavily pre-treated patients with advanced cutaneous T-Cell lymphoma (CTCL), 92% DCR in 15 evaluable CTCL patients:**
  - 1 CR: Sézary Syndrome (SS) ongoing at two years
  - 5 PR: 4 Mycosis Fungoides (MF), 1 SS

  2 evaluable patients with PTCL whereof 1 PR
- **50% ORR in combination with KEYTRUDA® (pembrolizumab)**
- **Favorable safety profile with mostly mild to moderate treatment-related adverse events**
- Immune activation observed early on, with depletion of regulatory T cells and an influx of CD8+ T cells into the skin



Orphan Drug Designation for TCL

Fast Track Designation for CTCL

WHAT'S NEXT? Additional monotherapy and combination data June 2026 (EHA)

CTCL: Cutaneous T-cell Lymphoma, PTCL: Peripheral T-cell Lymphoma

ANTI-FcγRIIB

BI-1206 in Non-Hodgkin's Lymphoma (NHL)

BI-1206 in Solid Tumors

BI-1206 in NHL

Paired with Entrenched Rituximab, BI-1206 can Compete in a Highly Competitive FL Market

Now



Follicular Lymphoma (FL) Market Shifts

- Increasing bispecific options
- Expansion of other MOAs (BTKi, CAR-T)
- Switch to rituximab biosimilars

2030



Opportunities for BI-1206

- Capturing 2nd line after 1st line bispecific (CD19XCD3)
- First anti-CD20 after bispecific will increase response rates of the triplet
- Safe and convenient, community hospital-friendly backbone (no CRS, neurotoxicity, neutropenia, infections, or hospital logistics associated with bispecifics/CAR-Ts)
- Combines with biosimilar rituximab, which remains the drug of choice for a majority of hematologists

Eversana market research
CRS: Cytokine Release Syndrome

Need for More Convenient, Safer Treatments for R/R Follicular Lymphoma

Similar Treatments	Infection Rates	Adverse Events
Lenalidomide-based regimens • Prolonged **management of side effects** requiring frequent clinic visits and monitoring Revlimid (lenalidomide) capsules	63%	50%
Bispecific T-cell engagers • **45-65%** of patients experience **CRS**[1] • Frequent clinic visits and hospital admissions required Lunsumio mosunetuzumab-axgb epkinly epcoritamab-bysp	45-50%	20-30%
CAR-T • Antibiotic treatment and IVIG infusions required • Treatment at **specialized centers** requiring in-patient stays and frequent visits • Very **high cost** YESCARTA (axicabtagene ciloleucel) KYMRIAH (tisagenlecleucel)	>50%	30-40%

Grade 3-4 neutropenia

Prolonged cytopenias

In contrast:
BI-1206 + Rituximab + acalabrutinib is an effective, convenient treatment that is easily administered, **well-tolerated**, with **no associated severe toxicities**

Source: Desk research based on public sources
1. Cytokine Release Syndrome

BI-1206 + Rituximab + Acalabrutinib* Best Response (FL, MZL, MCL)

Impressive Phase 2a data (20 evaluable patients)

- **ORR of 80%, CRR of 35% and DCR of 100%**
- Best clinical response:
  - 7 CR
  - 9 PR
  - 4 SD
- In FL subgroup ORR 77%
- The treatment has been well-tolerated with no safety or tolerability concerns



WHAT'S NEXT? Additional Phase 2a triplet data June 2026 (EHA)

*Supplied by AstraZeneca
FL: Follicular Lymphoma, MZL: Marginal Zone Lymphoma, MCL: Mantle Cell Lymphoma

BI-1206 in NHL: Combination with Rituximab and Acalabrutinib

Potential Timelines*



*Depending on partnering discussions and acceptance of development plan by FDA

BI-1206 in Solid Tumors:
Non-Small Cell Lung Cancer
Uveal Melanoma

Co-administration of BI-1206 with Pembrolizumab - Promising Responses in Uveal Melanoma Who Previously Failed anti-PD-1

Case study: PR

69 YO female with uveal melanoma.
No response to prior immunotherapy or chemotherapy. Multiples lines of ICIs and Chemo. Progressing when entering study. Showed early partial response at first scan on BI-1206 + pembrolizumab, continued PR deepening during whole study duration (2 years) with tumor burden reduced by 56% at end of trial.



Baseline

End of treatment 2 years



Competitive Landscape in PD-L1 high NSCLC



Key - Size of bubble : No. of pts.; Colored Bubbles : Approved treatments in US or EU; Grey Bubbles : Unapproved treatments; ¤ : China-run trial

Main toxicities : ICI : Pneumonitis, colitis, hepatitis, severe skin reactions. ICI + Chemo : Increased risk/severity of irAEs, Pneumonitis, sepsis. ICI+ TKI : Markedly increased ILD/pneumonitis

Phase 2a study Ongoing: BI-1206 + KEYTRUDA in Treatment-Naïve Patients

- To evaluate safety and efficacy of BI-1206 in combination with pembrolizumab
- Advanced or metastatic NSCLC and uveal melanoma
- Patients will be enrolled at sites in Georgia, Germany, Poland, Romania, Spain, Sweden and the US

BI-1206 combo with pembrolizumab

MSD



WHAT'S NEXT? First Phase 2a data in front-line NSCLC and uveal melanoma H2 2026E

* modified Toxicity Probability Interval 2



BioInvent

Unleashing Immunity
To Fight Cancer

www.bioinvent.com

Anti-PD-1 is Well Entrenched in 1st Line NSCLC (TPS > 50)

Pembrolizumab monotherapy is the standard of care in 1st line NSCLC (TPS > 50)

Anti-PD1 Ab

KEYTRUDA® (pembrolizumab) Injection 100 mg

- Treatment of choice as a single agent, 1st line (35% patients are TPS high)
- Generally well tolerated; toxicities can include pneumonitis, colitis
- 85,000 – 95,000 lung cancer patients eligible annually in 7 major markets

Anti-PD-1 + Anti-CTLA4

OPDIVO® (nivolumab)

YERVOY™ (ipilimumab)

- Approved for 1st line NSCLC but reserved as an alternative to chemoimmunotherapy
- Significant toxicities are common and include immune-mediated colitis, pneumonitis, hepatitis

Anti PD-L1 Ab

TECENTRIQ® atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE

- Not the preferred choice compared to pembro
- Could have slightly more favorable toxicity profile

Chemoimmunotherapy

- In combination with anti-PD1
- Carboplatin, pemetrexed, paclitaxel depending on tumor type and other factors
- Typical toxicities associated with chemotherapy

Lung Cancer Backgrounder

- American Cancer Society



- NSCLC accounts for approximately 85% of all diagnosed lung cancer cases globally.
- Lung cancer is the leading cause of cancer-related death worldwide, with over 2.5 million new cases diagnosed in 2022. Metastatic NSCLC has a 5-year survival of 12%.
- The NSCLC therapeutics market is projected to exceed $70 Billion by 2034, driven by a CAGR ~12%
- Key treatments include:
  - Targeted Therapy for patients with specific mutations (e.g., EGFR, ALK)
  - Immunotherapy
- Despite treatment advances, NSCLC faces major challenges, including the fact that 80% of cases are diagnosed at an advanced stage and the development of drug resistance to targeted therapies.

Only Two Treatments with Limited Efficacy are Approved for Metastatic Uveal Melanoma

CD3-gp100 fusion protein

KIMMTRAK® (tebentafusp-tebn)
Injection for Intravenous Use 100 mcg/0.5 mL

- Approval restricted to HLA-A*02:01 positive patients (40-50%)
- Common toxicities include CRS, severe skin reactions, and liver enzyme elevation

Liver directed

HEPZATO KIT™
(melphalan) for Injection/
Hepatic Delivery System (HDS)

- Percutaneous hepatic perfusion: liver-directed infusion of melphalan to treat liver mets
- Black box warning for hematological toxicities (thrombocytopenia)
- Complex procedure with risk of liver damage, bleeding

Anti-PD-1 + Anti-CTLA-4

OPDIVO® (nivolumab)
YERVOY™ (ipilimumab)

- Frequently used off-label
- Significant toxicities are common and include immune-mediated colitis, pneumonitis, hepatitis

- > 50% of patients are not eligible for tebentafusp
- Immunotherapies and chemotherapy, while used off label, are not effective
- Clinical-stage drugs to watch:
  - Darovasertib (PKC inhibitor): Targets GNAQ/GNA11 mutations (80% mUM) Phase 2/3
  - RP2 (oncolytic virus)+ anti-PD1
  - Sitravatinib (kinase inhibitor) + anti-PD1